Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Binimetinib

f9416d2c-9018-5d3a-89af-90d2127a0fba · FDA Approved · targets MEK1, MEK2

Binimetinib

MeasuredReference

Binimetinib has no high-confidence primary targets in the catalog. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

No high-confidence primary targets.

Top hallmarks

  • tumor promoting inflammation498
  • evading apoptosis494
  • proliferation489

Top pathways disrupted

  • pi3k akt mtor signaling995
  • apoptosis923
  • apical junction872

Resistance landscape — Binimetinib

MeasuredReference

1 known oncogenic variants exist on Binimetinib's top targets — see detail for inhibition impact.

Open in new tab